NewAmsterdam Pharma
NewAmsterdam Pharma
Explore linked clinical trials.7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-09-28 | NCT07794670 | |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | Dyslipidemias, Insulin Resistance, Lipid Metabolism Disorders, Lipidemia, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperinsulinism, hyperlipidemia, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2026-09-09 | NCT07219602 | |
| Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, metabolic disease | Recruiting | Phase 2 | 2026-04-09 | NCT06496243 | |
| A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | Arterial Occlusive Diseases, Dyslipidemias, Lipid Metabolism Disorders, Lipidemia, Nutritional and Metabolic Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Active, not recruiting | Phase 3 | 2026-04-09 | NCT06305559 | |
| Impact of the Corrie Lipids Digital Health Program on Lipid Optimization | Cardiovascular Risk; Digital Health; Implementation Science; LDL-C; Lipids | Recruiting | Not applicable | 2026-03-18 | NCT07478887 | |
| Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | Antioxidant Absorption | Recruiting | Phase 2 | 2025-10-20 | NCT06982508 | |
| Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2024-06-04 | NCT05202509 |